In this episode we explore the recent consumer trend for prescription weight loss drugs like Novo Nordisk's Wegovy with gut health expert Stephen O’Hara. As CEO of microbiome specialists OptiBiotix Health, O’Hara points to over-the-counter alternatives like prebiotic food supplements and medical devices, which may offer similar hunger-reducing benefits without the side effects associated with these drugs, which are designed for clinically obese patients. By successfully negotiating health claim regulatory frameworks, as well as investing in new markets and in new delivery formats like gummies, companies like Optibiotix are looking to take advantage of this new interest in slimming solutions, he explains.